News

EveryLife Introduces First of Kind ‘Roadmap’ to ICD Codes

To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…

Immunosuppressants May Reduce Risk of Ocular MG Progressing to gMG

Treatment with immunosuppressant medications can delay disease progression in patients with ocular myasthenia gravis, which affects only eye muscles, to a more generalized form in which other muscles are affected, a study has found. The findings also showed that thymus gland abnormalities, as well as irregular results on facial…

Poor Lung Function, Steroid Use Tied to Risk of Severe COVID-19

Poor lung function and disease management, along with previous long-term use of corticosteroids, older age, and the presence of cancer are the most significant predictors of severe COVID-19 among people with myasthenia gravis (MG), according to a recent study. The findings also indicated that the odds of death…

Study: MG Patients Not at Increased Risk for Atrial Fibrillation

People with myasthenia gravis (MG) are not at a higher risk of developing atrial fibrillation, a potentially serious heart condition that causes the heart to beat irregularly and often faster than normal, a study from Taiwan reports. The study, “Risk of subsequent atrial fibrillation in patients with myasthenia…

Immunovant Planning Pivotal Trial of IMVT-1401

Following a review of available clinical data, Immunovant has announced plans to resume clinical testing of the investigational medication IMVT-1401 in myasthenia gravis (MG) and other autoimmune conditions. Following discussions with regulatory agencies, the company is planning to launch a potentially pivotal trial of IMVT-1401 in…

2021 Myasthenia Gravis Survey Results

BioNews Survey Infographic

Myasthenia Gravis News conducted a survey from Feb. 11-March 28 to gain greater insight into the characteristics of the MG community and disease management. Results of the survey have now been published. Click on the image to view the infographic, and click here to read the story.